Despite of the increasing interest in immunotherapy against cancer, in breast cancer, only anti-HER2 monoclonal antibodies and PD-L1 inhibitors combined with conventional chemotherapy are used in current clinical practice in HER2+ (107, 108) and triple-negative breast cancer patients (TNBC), respectively (109, 110). This evidence concerns the gene ERBB2 and breast cancer.